Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

References

• Mughal T. Current and future use of hematopoietic growth factors in cancer medicine. Hematol Oncol 2004;22:121-34
   PubMed Web of Science ®Google Scholar
• Valley AW. New treatment options for managing chemotherapy-induced neutropenia. Am J Health Syst Pharm 2002;59:S11-17
   Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations of the use of white blood cell growth factors: an evidence-based clinical practice guidelines. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Crawford J. Pegfilgrastim: the promise of pegylation fulfilled. Ann Oncol 2003;14:6-7
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Standaert B, Goldstone J, Lu ZJ, et al. Economic analysis of filgrastim use for patients with acute myeloid leukemia in the UK: a comparison of collection methods of resource use data. Pharmacoeconomics 2002;20:665-74
   PubMed Web of Science ®Google Scholar
• Bennett CL, Stinson TJ, Lane D, et al. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-Cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Ped Oncol 2000;34:92-6
   PubMedGoogle Scholar
• Berstein BJ, Blanchard LM. Economic and clinical impact of a pharmacy-based filgrastim protocol in oncology patients. Am J Health Syst Pharm 1999;56:1330-3
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small cell lung cancer. J Clin Oncol 2006;24:2991-7
   PubMed Web of Science ®Google Scholar
• Haithcox S, R Ramnes C, Lee H, et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs 2003;2:2
   PubMedGoogle Scholar
• O’Brien B, Gafni A. When do the “dollars” make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996;16:288-99
   PubMed Web of Science ®Google Scholar
• Gafni A. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decision making about health care programs. Med Care 1991;29:1246-52
   PubMed Web of Science ®Google Scholar
• Fortner BV, Schwartzberg L, Tauer K, et al. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005l;13:522-8
   PubMed Web of Science ®Google Scholar
• Fortner BV, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer 2004;4:22
   PubMed Web of Science ®Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increases risk of hospitalization? Oncology 2006;40:402-6
   Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001;6:441-5
   PubMed Web of Science ®Google Scholar
• Cosler LE, Calhoun EA, Agboola O, et al. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488-94
   PubMed Web of Science ®Google Scholar
• Adams JR. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol 2006;24:2975-7
   PubMed Web of Science ®Google Scholar
• Chouaid C, Molinier L, Combescure C, et al. Economic evaluation of the clinical management of lung cancer in France. Br J Cancer 2004;90:397-402
   PubMed Web of Science ®Google Scholar
• Klose T. The contingent valuation method in health care. Health Policy 1999;47:97-123
   PubMed Web of Science ®Google Scholar
• Gafni A. Willingness to pay: what's in a name. Pharmacoeconomics 1998;14:465-70
   PubMed Web of Science ®Google Scholar
• Olsen J. Aiding priority setting in health care: is there a role for the contingent valuation method? Health Econ 1997;6:603-12
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Elia-Pacitti J, Cottrell W. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics 2004;22:375-87
   PubMed Web of Science ®Google Scholar
• Aristides M, Chen J, Schulz M, et al. Conjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer. Pharmacoeconomics 2002;20:775-84
   PubMed Web of Science ®Google Scholar